Expert Insights

In a debate at the 2023 Great Debates & Updates in Hematologic Malignancies conference in New York, New York, Elizabeth A. Brem, MD, analyzed the role of central nervous system prophylaxis for patients with DLBCL.

At the 2023 Great Debates and Updates in Gastrointestinal Malignancies meeting, Joseph Herman, MD, discussed the argument against use of radiotherapy in borderline resectable pancreas cancer.

At the 2023 Great Debates and Updates in Gastrointestinal Malignancies meeting, Lisa Kachnic, MD, discussed the argument against use of radiotherapy in borderline resectable pancreas cancer.

Anup Kasi, MD, discusses the debate on neoadjuvant vs adjuvant immunotherapy for patients with locally advanced HER2-positive upper gastrointestinal tract cancers, held at the 2023 Great Debates and Updates in GI Malignancies in Chicago.

Claire Harrison, MD, discusses the latest updates in diagnostics and risk stratification of polycythemia vera with Jean-Jacques Kiladjian, MD, and Alessandro Rambaldi, MD.

At the 2023 Great Debates & Updates in Hematologic Malignancies in New York, New York, Jennifer Amengual, MD, discussed the process of choosing among non-CAR-T options for patients with recurrent aggressive lymphoma, particularly DLBCL.

Basil Njei, MD, MPH, PhD, discusses his research into the use of artificial intelligence in the detection of malignant biliary strictures and cholangiocarcinoma.

Margarita Sánchez-Beato, PhD, discusses the monitoring of circulating tumor DNA to predict response to treatment and early progression among patients with follicular lymphoma.

Arvind Dasari, MD, discusses the important points clinicians should consider when treating patients with neuroendocrine tumors.

Arvind Dasari, MD, reviews the new and upcoming treatment options for patients with neuroendocrine tumors at the 2023 Great Debates and Updates in GI Malignancies in Chicago.